Substituent effects on desferrithiocin and desferrithiocin analogue iron-clearing and toxicity profiles

Journal of Medicinal Chemistry

Volumn 55, Issue 16, 2012, Pages 7090-7103

  Bergeron, Raymond J ^a   Wiegand, Jan ^a   Bharti, Neelam ^a   McManis, James S ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4,5 DIHYDRO 2 (3,5 DIHYDROXY 2 PYRIDINYL) 4 METHYL 4 THIAZOLECARBOXYLIC ACID; 4,5 DIHYDRO 2 [3 HYDROXY 4 (3,6 DIOXAHEPTYLOXY) 2 PYRIDINYL] 4 METHYL 4 THIAZOLECARBOXYLIC ACID; 4,5 DIHYDRO 2 [3 HYDROXY 5 (3,6 DIOXAHEPTYLOXY) 2 PYRIDINYL] 4 METHYL 4 THIAZOLECARBOXYLIC ACID; DEFERRIFERRITHIOCIN; DEFERRIFERRITHIOCIN DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG STRUCTURE; DRUG SYNTHESIS; IRON CHELATION; NEPHROTOXICITY; NONHUMAN; RAT; REACTION ANALYSIS; STRUCTURE ANALYSIS; TOXICITY TESTING;

ADMINISTRATION, ORAL; ANIMALS; CEBUS; COORDINATION COMPLEXES; DIHYDROPYRIDINES; ETHERS; FERRIC COMPOUNDS; HYDROXYLATION; IRON CHELATING AGENTS; IRON OVERLOAD; KIDNEY; LIGANDS; MALE; RATS; RATS, SPRAGUE-DAWLEY; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES;

EID: 84866893003     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm300509y     Document Type: Article

References (74)

1. Raymond, K. N.; Carrano, C. J. Coordination Chemistry and Microbial Iron Transport. Acc. Chem. Res. 1979, 12, 183-190.
2. Byers, B. R.; Arceneaux, J. E. Microbial Iron Transport: Iron Acquisition by Pathogenic Microorganisms. Met. Ions Biol. Syst. 1998, 35, 37-66.
3. Bergeron, R. J. Iron: A Controlling Micronutrient in Proliferative Processes. Trends Biochem. Sci. 1986, 11, 133-136.
4. Theil, E. C.; Huynh, B. H. Ferritin Mineralization: Ferroxidation and Beyond. J. Inorg. Biochem. 1997, 67, 30.
5. Ponka, P.; Beaumont, C.; Richardson, D. R. Function and Regulation of Transferrin and Ferritin. Semin. Hematol. 1998, 35, 35-54.
6. Brittenham, G. M. Disorders of Iron Metabolism: Iron Deficiency and Overload. In Hematology: Basic Principles and Practice, 3rd ed.; Hoffman, R., Benz, E. J., Shattil, S. J., Furie, B., Cohen, H. J., et al., Eds.; Churchill Livingstone: New York, 2000; pp 397-428.
7. Olivieri, N. F.; Brittenham, G. M. Iron-Chelating Therapy and the Treatment of Thalassemia. Blood 1997, 89, 739-761.
8. Vichinsky, E. P. Current Issues with Blood Transfusions in Sickle Cell Disease. Semin. Hematol. 2001, 38, 14-22.
9. Kersten, M. J.; Lange, R.; Smeets, M. E.; Vreugdenhil, G.; Roozendaal, K. J.; Lameijer, W.; Goudsmit, R. Long-Term Treatment of Transfusional Iron Overload with the Oral Iron Chelator Deferiprone (L1): A Dutch Multicenter Trial. Ann. Hematol. 1996, 73, 247-252.
10. Conrad, M. E.; Umbreit, J. N.; Moore, E. G. Iron Absorption and Transport. Am. J. Med. Sci. 1999, 318, 213-229.
11. Lieu, P. T.; Heiskala, M.; Peterson, P. A.; Yang, Y. The Roles of Iron in Health and Disease. Mol. Aspects Med. 2001, 22, 1-87.
12. Graf, E.; Mahoney, J. R.; Bryant, R. G.; Eaton, J. W. Iron-Catalyzed Hydroxyl Radical Formation. Stringent Requirement for Free Iron Coordination Site. J. Biol. Chem. 1984, 259, 3620-3624.
13. Halliwell, B. Iron, Oxidative Damage, and Chelating Agents. In The Development of Iron Chelators for Clinical Use; Bergeron, R. J., Brittenham, G. M., Eds.; CRC: Boca Raton, FL, 1994; pp 33-56.
14. Koppenol, W. Kinetics and Mechanism of the Fenton Reaction: Implications for Iron Toxicity. In Iron Chelators: New Development Strategies; Badman, D. G., Bergeron, R. J., Brittenham, G. M., Eds.; Saratoga: Ponte Vedra Beach, FL, 2000; pp 3-10.
15. Hazen, S. L.; d'Avignon, A.; Anderson, M. M.; Hsu, F. F.; Heainecke, J. W. Human Neutrophils Employ the Myeloperoxidase- Hydrogen Peroxide- Chloride System to Oxidize α-Amino Acids to a Family of Reactive Aldehydes. Mechanistic Studies Identifying Labile Intermediates along the Reaction Pathway. J. Biol. Chem. 1998, 273, 4997-5005.
16. Millan, M.; Sobrino, T.; Arenillas, J. F.; Rodriguez-Yanez, M.; García, M.; Nombela, F.; Castellanos, M.; de la Ossa, N. P.; Cuadras, P.; Serena, J.; Castillo, J.; Davalos, A. Biological Signatures of Brain Damage Associated with High Serum Ferritin Levels in Patients with Acute Ischemic Stroke and Thrombolytic Treatment. Dis. Markers 2008, 25, 181-188.
17. Zecca, L.; Casella, L.; Albertini, A.; Bellei, C.; Zucca, F. A.; Engelen, M.; Zadlo, A.; Szewczyk, G.; Zareba, M.; Sarna, T. Neuromelanin Can Protect Against Iron-Mediated Oxidative Damage in System Modeling Iron Overload of Brain Aging and Parkinson's Disease. J. Neurochem. 2008, 106, 1866-1875.
18. Pietrangelo, A. Iron Chelation Beyond Tranfusion Iron Overload. Am. J. Hematol. 2007, 82, 1142-1146.
19. Dunaief, J. L. Iron Induced Oxidative Damage as a Potential Factor in Age-Related Macular Degeneration: The Cogan Lecture. Invest. Ophthalmol. Vis. Sci. 2006, 47, 4660-4664.
20. Hua, Y.; Nakamura, T.; Keep, R. F.; Wu, J.; Schallert, T.; Hoff, J. T.; Xi, G. Long-Term Effects of Experimental Intracerebral Hemorrhage: The Role of Iron. J. Neurosurg. 2006, 104, 305-312.
21. Pippard, M. J. Iron Overload and Iron Chelation Therapy in Thalassaemia and Sickle Cell Haemoglobinopathies. Acta Haematol. 1987, 78, 206-211.
22. Olivieri, N. F. Progression of Iron Overload in Sickle Cell Disease. Semin. Hematol. 2001, 38, 57-62.
23. Malcovati, L. Impact of Transfusion Dependency and Secondary Iron Overload on the Survival of Patients with Myelodysplastic Syndromes. Leuk. Res. 2007, 31, S2-S6.
24. Kalinowski, D. S.; Richardson, D. R. The Evolution of Iron Chelators for the Treatment of Iron Overload Disease and Cancer. Pharm. Rev. 2005, 57, 547-583.
25. Brittenham, G. M. Iron-Chelating Therapy for Transfusional Iron Overload. N. Engl. J. Med. 2011, 364, 146-156.
26. Desferal; Novartis Pharmaceuticals Corporation: East Hanover, NJ, 2008; http://www.pharma.us.novartis.com/product/pi/pdf/desferal.pdf.
27. Hoffbrand, A. V.; Al-Refaie, F.; Davis, B.; Siritanakatkul, N.; Jackson, B. F. A.; Cochrane, J.; Prescott, E.; Wonke, B. Long-Term Trial of Deferiprone in 51 Transfusion-Dependent Iron Overloaded Patients. Blood 1998, 91, 295-300.
28. Olivieri, N. F. Long-Term Therapy with Deferiprone. Acta Haematol. 1996, 95, 37-48.
29. Olivieri, N. F.; Brittenham, G. M.; McLaren, C. E.; Templeton, D. M.; Cameron, R. G.; McClelland, R. A.; Burt, A. D.; Fleming, K. A. LongTerm Safety and Effectiveness of Iron-Chelation Therapy with Deferiprone from Thalassemia Major. N. Engl. J. Med. 1998, 339, 417-423.
30. Richardson, D. R. The Controversial Role of Deferiprone in the Treatment of Thalassemia. J. Lab. Clin. Med. 2001, 137, 324-329.
31. Nisbet-Brown, E.; Olivieri, N. F.; Giardini, P. J.; Grady, R. W.; Neufeld, E. J.; Sechaud, R.; Krebs-Brown, A. J.; Anderson, J. R.; Alberti, D.; Sizer, K. C.; Nathan, D. G. Effectiveness and Safety of ICL670 in Iron-Loaded Patients with Thalassemia: A Randomised, Double-Blind, Placebo-Controlled, Dose-Escalation Trial. Lancet 2003, 361, 1597-1602.
32. Galanello, R.; Piga, A.; Alberti, D.; Rouan, M.-C.; Bigler, H.; Sechaud, R. Safety, Tolerability, and Pharmacokinetics of ICL670, a New Orally Active Iron-Chelating Agent in Patients with Transfusion-Dependent Iron Overload Due to β-Thalassemia. J. Clin. Pharmacol. 2003, 43, 565-572.
33. Cappellini, M. D. Iron-Chelating Therapy with the New Oral Agent ICL670 (Exjade). Best Pract. Res. Clin. Haematol. 2005, 18, 289-298.
34. Exjade Prescribing Information; Novartis Pharmaceuticals Corporation: East Hanover, NJ, March, 2012; http://www.pharma.us. novartis.com/product/pi/ pdf/exjade.pdf.
35. Pippard, M. J. Desferrioxamine-Induced Iron Excretion in Humans. Bailliere's Clin. Haematol. 1989, 2, 323-343.
36. Giardina, P. J.; Grady, R. W. Chelation Therapy in β-Thalassemia: An Optimistic Update. Semin. Hematol. 2001, 38, 360-366.
37. Bergeron, R. J.; Streiff, R. R.; Creary, E. A.; Daniels, R. D., Jr.; King, W.; Luchetta, G.; Wiegand, J.; Moerker, T.; Peter, H. H. A Comparative Study of the Iron-Clearing Properties of Desferrithiocin Analogues with Desferrioxamine B in a Cebus Monkey Model. Blood 1993, 81, 2166-2173.
38. Bergeron, R. J.; Wiegand, J.; McManis, J. S.; McCosar, B. H.; Weimar, W. R.; Brittenham, G. M.; Smith, R. E. Effects of C-4 Stereochemistry and C-4′ Hydroxylation on the Iron Clearing Efficiency and Toxicity of Desferrithiocin Analogues. J. Med. Chem. 1999, 42, 2432-2440.
39. Bergeron, R. J.; Wiegand, J.; McManis, J. S.; Bussenius, J.; Smith, R. E.; Weimar, W. R. Methoxylation of Desazadesferrithiocin Analogues: Enhanced Iron Clearing Efficiency. J. Med. Chem. 2003, 46, 1470-1477.
40. Bergeron, R. J.; Wiegand, J.; Weimar, W. R.; Vinson, J. R. T.; Bussenius, J.; Yao, G. W.; McManis, J. S. Desazadesmethyldesferrithio-cin Analogues as Orally Effective Iron Chelators. J. Med. Chem. 1999, 42, 95-108.
41. Galanello, R.; Forni, G.; Jones, A.; Kelly, A.; Willemsen, A.; He, X.; Johnston, A.; Fuller, D.; Donovan, J.; Piga, A. A Dose Escalation Study of the Pharmacokinetics, Safety, and Efficacy of Deferitrin, an Oral Iron Chelator in Beta Thalassaemia Patients. ASH Annu. Meet. Abstr. 2007, 110, 2669.
42. Bergeron, R. J.; Wiegand, J.; McManis, J. S.; Vinson, J. R. T.; Yao, H.; Bharti, N.; Rocca, J. R. (S)-4, 5-Dihydro-2-(2-hydroxy-4-hydrox-yphenyl)-4- methyl-4-thiazolecarboxylic Acid Polyethers: A Solution to Nephrotoxicity. J. Med. Chem. 2006, 49, 2772-2783.
43. Bergeron, R. J.; Wiegand, J.; Bharti, N.; Singh, S.; Rocca, J. R. Impact of 3, 6, 9-Trioxadecyloxy Group on Desazadesferrithiocin Analogue Iron Chelators and Organ Distribution. J. Med. Chem. 2007, 50, 3302-3313.
44. Naegeli, H.-U.; Zahner, H. Metabolites of Microorganisms. Part 193. Ferrithiocin. Helv. Chim. Acta 1980, 63, 1400-1406.
45. Hahn, F. E.; McMurry, T. J.; Hugi, A.; Raymond, K. N. Coordination Chemistry of Microbial Iron Transport. 42. Structural and Spectroscopic Characterization of Diastereomeric Cr(III) and Co(III) Complexes of Desferriferrithiocin. J. Am. Chem. Soc. 1990, 112, 1854-1860.
46. Anderegg, G.; Raber, M. Metal Complex Formation of a New Siderophore Desferrithiocin and of Three Related Ligands. J. Chem. Soc., Chem. Commun. 1990, 1194-1196.
47. Bergeron, R. J.; Wiegand, J.; Dionis, J. B.; Egli-Karmakka, M.; Frei, J.; Huxley-Tencer, A.; Peter, H. H. Evaluation of Desferrithiocin and Its Synthetic Analogues as Orally Effective Iron Chelators. J. Med. Chem. 1991, 34, 2072-2078.
48. Bergeron, R. J.; Streiff, R. R.; Wiegand, J.; Vinson, J. R. T.; Luchetta, G.; Evans, K. M.; Peter, H.; Jenny, H.-B. A Comparative Evaluation of Iron Clearance Models. Ann. N.Y. Acad. Sci. 1990, 612, 378-393.
49. Wolfe, L. C.; Nicolosi, R. J.; Renaud, M. M.; Finger, J.; Hegsted, M.; Peter, H.; Nathan, D. G. A Non-Human Primate Model for the Study of Oral Iron Chelators. Br. J. Hamaetol. 1989, 72, 456-461.
50. Sangster, J. Octanol-Water Partition Coefficients: Fundamentals and Physical Chemistry; John Wiley and Sons: West Sussex, England, 1997; Vol. 2.
51. Bergeron, R. J.; McManis, J. S.; Weimar, W. R.; Wiegand, J.; Eiler-McManis, E. Iron Chelators and Therapeutic Uses. In Burger's Medicinal Chemistry, 6th ed.; Abraham, D. A., Ed.; Wiley: New York, 2003; pp 479-561.
52. Bergeron, R. J.; Wiegand, J.; McManis, J. S.; Bharti, N.; Singh, S. Desferrithiocin Analogues and Nephrotoxicity. J. Med. Chem. 2008, 51, 5993-6004.
53. Bergeron, R. J.; Wiegand, J.; McManis, J. S.; Bharti, N.; Singh, S. Design, Synthesis, and Testing of Non-Nephrotoxic Desazadesferri-thiocin Polyether Analogues. J. Med. Chem. 2008, 51, 3913-3923.
54. Bergeron, R. J.; Bharti, N.; Wiegand, J.; McManis, J. S.; Singh, S.; Abboud, K. A. The Impact of Polyether Chain Length on the Iron Clearing Efficiency and Physiochemical Properties of Desferrithiocin Analogues. J. Med. Chem. 2010, 53, 2843-2853.
55. Bergeron, R. J.; Wiegand, J.; Bharti, N.; McManis, J. S.; Singh, S. Desferrithiocin Analogue Iron Chelators: Iron Clearing Efficiency, Tissue Distribution, and Renal Toxicity. Biometals 2011, 24, 239-258.
56. Feau, C.; Klein, E.; Kerth, P.; Lebeau, L. Preparation and Optical Properties of Novel 3-Alkoxycarbonyl Aza- and Diazacoumarins. Synth. Commun. 2010, 40, 3033-3045.
57. Ornelas, M. A.; Gonzalez, J.; Sach, N. W.; Richardson, P. F.; Bunker, K. D.; Linton, A.; Kephart, S. E.; Pairish, M.; Guo, C. An Efficient Synthesis of Highly Functionalized Chiral Lactams. Tetrahedron Lett. 2011, 52, 4760-4763.
58. Bergeron, R. J.; Bharti, N.; Singh, S.; McManis, J. S.; Wiegand, J.; Green, L. G. Vibriobactin Antibodies: A Vaccine Strategy. J. Med. Chem. 2009, 52, 3801-3813.
59. Marriott, J. H.; Moreno-Barber, A. M.; Hardcastle, I. R.; Rowlands, M. G.; Grimshaw, R. M.; Neidle, S.; Jarman, M. Synthesis of the Farnesyl Ether 2, 3, 5-Trifluoro-6-hydroxy-4-[(E, E)-3, 7, 11-tri-methyldodeca-2, 6, 10-trien-1-yloxy]nitrobenzene, and Related Compounds Containing a Substituted Hydroxytrifluorophenyl Residue: Novel Inhibitors of Protein Farnesyltransferase, Geranylgeranyltransferase I and Squalene Synthase. J. Chem. Soc., Perkin Trans. 2000, 1, 4265-4278.
60. Piyamongkol, S.; Liu, Z. D.; Hider, R. C. Novel Synthetic Approach to 2-(1′-Hydroxyalkyl)- and 2-Amido-3-Hydroxypyridin-4-ones. Tetrahedron 2001, 57, 3479-3486.
61. Li, M.-J.; Kwok, W.-M.; Lam, W. H.; Tao, C.-H.; Yam, V. W.-W.; Phillips, D. L. Synthesis of Coumarin-Appended Pyridyl Tricarbonyl-rhenium (I) 2, 2′-Bipyridyl Complexes with Oligoether Spacer and Their Fluorescence Resonance Energy Transfer Studies. Organometallics 2009, 28, 1620-1630.
62. Bergeron, R. J.; Wiegand, J.; Weimar, W. R.; McManis, J. S.; Smith, R. E.; Abboud, K. A. Iron Chelation Promoted by Desazadesferrithiocin Analogs: An Enantioselective Barrier. Chirality 2003, 15, 593-599.
63. Hoffmann, D.; Fuchs, T. C.; Henzler, T.; Matheis, K. A.; Herget, T.; Dekant, W.; Hewitt, P.; Mally, A. Evaluation of a Urinary Kidney Biomarker Panel in Rat Models of Acute and Subchronic Nephrotox-icity. Toxicology 2010, 277, 49-58.
64. Han, W. K.; Bailly, V.; Abichandani, R.; Thadhani, R.; Bonventre, J. V. Kidney Injury Molecule-1 (KIM-1): A Novel Biomarker for Human Renal Proximal Tubule Injury. Kidney Int. 2002, 62, 237-244.
65. Bonventre, J. V. Kidney Injury Molecule-1 (KIM-1): A Urinary Biomarker and Much More. Nephrol., Dial., Transplant. 2009, 24, 3265-3268.
66. Zhou, Y.; Vaidya, V. S.; Brown, R. P.; Zhang, J.; Rosenzweig, B. A.; Thompson, K. L.; Miller, T. J.; Bonventre, J. V.; Goering, P. L. Comparison of Kidney Injury Molecule-1 and other Nephrotoxicity Biomarkers in Urine and Kidney Following Acute Exposure to Gentamicin, Mercury, and Chromium. Toxicol. Sci. 2008, 101, 159-170.
67. Vaidya, V. S.; Ramirez, V.; Ichimura, T.; Bobadilla, N. A.; Bonventre, J. V. Urinary Kidney Injury Molecule-1: A Sensitive Quantitative Biomarker for Early Detection of Kidney Tubular Injury. Am. J. Physiol. Renal Physiol. 2006, 290, F517-F529.
68. Bailly, V.; Zhang, Z.; Meier, W.; Cate, R.; Sanicola, M.; Bonventre, J. V. Shedding of Kidney Injury Molecule-1, A Putative Adhesion Protein Involved in Renal Regeneration. J. Biol. Chem. 2002, 277, 39739-39748.
69. Vaidya, V. S.; Ford, G. M.; Waikar, S. S.; Wang, Y.; Clement, M. B.; Ramirez, V.; Glaab, W. E.; Troth, S. P.; Sistare, F. D.; Prozialeck, W. C.; Edwards, J. R.; Bobadilla, N. A.; Mefferd, S. C.; Bonventre, J. V. A Rapid Urine Test for Early Detection of Kidney Injury. Kidney Int. 2009, 76, 108-114.
70. Antech Diagnostics; http://www.antechdiagnostics.com/(ac cessed March, 2012).
71. Bergeron, R. J.; Streiff, R. R.; Wiegand, J.; Luchetta, G.; Creary, E. A.; Peter, H. H. A Comparison of the Iron-Clearing Properties of 1, 2-Dimethyl-3-Hydroxypyrid-4-one, 1, 2-Diethyl-3-Hydroxypyrid-4-one, and Deferoxamine. Blood 1992, 79, 1882-1890.
72. Wood, J. K.; Milner, P. F.; Pathak, U. N. The Metabolism of Iron-Dextran Given As a Total-Dose Infusion to Iron Deficient Jamaican Subjects. Br. J. Hamaetol. 1968, 14, 119-129.
73. Bergeron, R. J.; Wiegand, J.; Brittenham, G. M. HBED: A Potential Alternative to Deferoxamine for Iron-Chelating Therapy. Blood 1998, 91, 1446-1452.
74. Bergeron, R. J.; Wiegand, J.; Wollenweber, M.; McManis, J. S.; Algee, S. E.; Ratliff-Thompson, K. Synthesis and Biological Evaluation of Naphthyldesferrithiocin Iron Chelators. J. Med. Chem. 1996, 39, 1575-1581.